



Retrophin to Report Fourth Quarter and Full Year 2014 Financial Results

February 19, 2015

SAN DIEGO--(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2014 financial results on Thursday, March 5, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Conference Call Information

Date: Thursday, March 5, 2015
Time: 4:30 p.m. ET
Dial-in numbers: +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)
Confirmation code: 91191559
Live webcast: www.retrophin.com in the "Events & Presentations" section of the "Investors" page

A replay of the call will be available 7:30 p.m. ET, March 5, 2015 to 11:59 p.m. ET, March 12, 2015. The replay number is 855-859-2056 (U.S.) or 404-537-3406 (International), confirmation code 91191559.

About Retrophin

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal® and Thiola® and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), infantile spasms, nephrotic syndrome and others. For additional information, please visit www.retrophin.com.

Retrophin, Inc.
Chris Cline, CFA, 646-564-3680
Manager, Investor Relations
IR@retrophin.com

Source: Retrophin, Inc.

News Provided by Acquire Media